PET-imaging of two Vartumabs (F8scFv and C9scFv) in patients with solid tumors – a Phase 0 basket trial
This clinical trial is testing two new imaging substances, known as Vartumabs, in adults with solid tumours. A PET scan is a common hospital scan that produces detailed pictures of the inside of the body using a tiny amount of a tracking dye. In this trial, researchers are giving a very small dose of a new tracer to see if it sticks to tumour cells and makes them show up clearly on the scan. This is a 'Phase 0' trial, which means it uses very low doses to test how the substance behaves in the human body, rather than to treat the cancer directly. The study is open to adults aged 18 and over with solid tumours. The main aim is to check if these new tracers are safe and useful for future cancer diagnosis and monitoring.
A colpo d'occhio
Di cosa tratta questo studio?
Getting a clear picture of a tumour is essential for choosing the best cancer treatment. Doctors often use PET scans, which use a mild tracking substance injected into the bloodstream to highlight areas of disease. This trial is looking at two new experimental tracers called Vartumabs (F8scFv and C9scFv) to see if they can improve how solid tumours are visualised.
Vartumabs are made from small fragments of antibodies, which are proteins designed to search for and attach to specific markers on cancer cells. When these fragments carry a tiny, safe amount of radiation, they act like a beacon. If they attach to tumour cells, the PET camera can detect them, showing doctors exactly where the cancer is.
This study is called a Phase 0 'basket trial'. The term 'basket' means it includes patients with different types of solid tumours—such as lung, bowel, or breast cancer—rather than just one type. Because it is Phase 0, the amount of tracer given is extremely small. The study is not designed to shrink or cure the cancer, but to test how well the imaging works. The results could help scientists develop more accurate scanning tools for cancer patients in the future.
Punti chiave
- Tests two new imaging dyes (Vartumabs) to improve cancer PET scans.
- Open to adults aged 18 and over with solid tumours.
- This is an imaging trial, not a cancer treatment.
- Involves a small injection into a vein followed by a PET scan.
- Participation is voluntary and does not replace your routine cancer care.
Chi può essere idoneo?
This trial is open to adults aged 18 and older who have been diagnosed with a solid tumour. A solid tumour is a cancer that forms a lump or mass in body tissues, such as the breast, bowel, or prostate, rather than a blood cancer like leukaemia.
To take part, you will need to be well enough to visit the hospital, have a small injection into a vein, and lie still inside a PET scanner for the duration of the scan. Your care team will check your overall health, including your kidney and liver function, to make sure taking part is safe for you.
You might not be able to take part if you are pregnant, planning to become pregnant, or breastfeeding. People with severe allergies to imaging dyes or certain other medical conditions may also be excluded. Your doctor can review the full checklist with you.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- I am aged 18 or over.
- I have been diagnosed with a solid tumour cancer.
- I am able to lie still in a scanner for up to an hour.
- I am not pregnant or breastfeeding.
- I am able to travel to the study hospital for scan appointments.
Cosa comporta la partecipazione?
Taking part involves attending a specialist hospital or scanning centre. A doctor or nurse will place a small needle (cannula) into a vein in your arm to inject the Vartumab tracer. You will then wait for a set period while the tracer moves through your body and binds to any tumour cells.
Next, you will have a PET scan, which involves lying flat on a padded table that gently slides into a ring-shaped scanner. The scan usually takes between 30 and 60 minutes. Staff will monitor you closely during and after the scan to check for any side effects. Your total time in the study is typically short—often just one or two visits covering the screening, the scan day, and a brief follow-up check.
Rischi e benefici potenziali
Luoghi (1)
- —Non verificatoPaesi Bassi
Domande comuni
Will this trial treat or cure my cancer?
No. This is an imaging study using very low doses to test a new scanning method. It is designed to take pictures of cancer, not to treat it.
What is a Phase 0 trial?
A Phase 0 trial is a very early study in humans that uses tiny, non-treatment doses to see how a new substance travels through the body and whether it reaches its target safely.
Is the radiation from the PET scan dangerous?
The scan uses a very small, carefully controlled amount of radiation, comparable to standard diagnostic tests. The study team ensures the dose is kept as low as reasonably possible.
Do I have to stop my regular cancer treatment to join?
This depends on the trial's exact schedule and your current treatment plan. Your cancer specialist will tell you whether joining fits safely alongside your current care.
Posso abbandonare lo studio se cambio idea?
Yes, you can leave the study at any point. You do not have to give a reason, and your normal medical care will continue as usual.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Interessato a partecipare?
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.